These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16208304)

  • 1. Insulin resistance and the metabolic syndrome as predictors of cardiovascular risk: where are we now?
    Sattar N
    Minerva Endocrinol; 2005 Sep; 30(3):121-38. PubMed ID: 16208304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance.
    Kendall DM; Harmel AP
    Am J Manag Care; 2002 Dec; 8(20 Suppl):S635-53; quiz S654-7. PubMed ID: 12510788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward an improved diagnosis of the metabolic syndrome other clues to the presence of insulin resistance.
    Cohn GS; Kittleson MM; Blumenthal RS
    Am J Hypertens; 2005 Aug; 18(8):1099-103. PubMed ID: 16109324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic syndrome and its cardiovascular manifestations.
    Sánchez-Torres RJ; Delgado-Osorio H
    Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges associated with metabolic syndrome.
    Spinler SA
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):209S-217S. PubMed ID: 17125447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
    Zarich SW
    Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic syndrome: definitions, prevalence and management.
    Levesque J; Lamarche B
    J Nutrigenet Nutrigenomics; 2008; 1(3):100-8. PubMed ID: 19776619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk.
    Smith SR
    Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():128S-134S. PubMed ID: 16931494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
    Grundy SM
    J Am Coll Cardiol; 2006 Mar; 47(6):1093-100. PubMed ID: 16545636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Ahmed I; Goldstein BJ
    Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.
    St George A; Bauman A; Johnston A; Farrell G; Chey T; George J
    J Gastroenterol Hepatol; 2009 Mar; 24(3):399-407. PubMed ID: 19067776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrovascular complications of metabolic syndrome: an early intervention is imperative.
    Tenenbaum A; Motro M; Schwammenthal E; Fisman EZ
    Int J Cardiol; 2004 Nov; 97(2):167-72. PubMed ID: 15458679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation.
    Onat A; Hergenç G; Türkmen S; Yazici M; Sari I; Can G
    Metabolism; 2006 Apr; 55(4):445-52. PubMed ID: 16546474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage.
    Mulé G; Cottone S; Nardi E; Andronico G; Cerasola G
    Minerva Cardioangiol; 2006 Apr; 54(2):173-94. PubMed ID: 16778751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
    Appel SJ; Harrell JS; Davenport ML
    J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.